Jacobs Levy Equity Management
ACOR

Jacobs Levy Equity Management’s Acorda Therapeutics ACOR Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,760
Closed -$645K – 1154
2021
Q2 		$645K Sell
6,760
-5,696
-46% -$498K ﹤0.01% 820
2021
Q1 		$1.21M Buy
12,456
+3,460
+38% +$425K 0.01% 696
2020
Q4 		$745K Buy
8,996
+1,619
+22% +$149K 0.01% 787
2020
Q3 		$456K Buy
7,377
+6,213
+534% +$468K ﹤0.01% 812
2020
Q2 		$103K Hold
1,164
– – ﹤0.01% 1003
2020
Q1 		$130K Sell
1,164
-8,951
-88% -$1.76M ﹤0.01% 940
2019
Q4 		$2.48M Buy
10,115
+1,881
+23% +$475K 0.02% 505
2019
Q3 		$2.84M Buy
8,234
+3,548
+76% +$1.93M 0.03% 441
2019
Q2 		$4.31M Sell
4,686
-626
-12% -$769K 0.06% 377
2019
Q1 		$8.47M Buy
5,312
+1,294
+32% +$2.33M 0.12% 218
2018
Q4 		$7.51M Buy
4,018
+245
+6% +$533K 0.13% 176
2018
Q3 		$8.9M Buy
3,773
+695
+23% +$2.15M 0.13% 192
2018
Q2 		$10.6M Buy
3,078
+31
+1% +$94.9K 0.17% 175
2018
Q1 		$8.65M Buy
3,047
+55
+2% +$165K 0.14% 199
2017
Q4 		$7.7M Buy
2,992
+440
+17% +$1.25M 0.14% 208
2017
Q3 		$7.24M Sell
2,552
-26
-1% -$68.5K 0.14% 207
2017
Q2 		$6.09M Buy
2,578
+426
+20% +$844K 0.13% 205
2017
Q1 		$5.42M Buy
2,152
+337
+19% +$970K 0.11% 235
2016
Q4 		$4.09M Buy
1,815
+1,307
+257% +$3.11M 0.08% 282
2016
Q3 		$1.27M Sell
508
-16
-3% -$47.7K 0.02% 521
2016
Q2 		$1.6M Sell
524
-266
-34% -$865K 0.03% 472
2016
Q1 		$2.51M Buy
+790
New +$3.28M 0.05% 356
2015
Q4 		– Sell
-425
Closed -$1.35M – 891
2015
Q3 		$1.35M Sell
425
-11
-3% -$42.7K 0.03% 431
2015
Q2 		$1.74M Sell
436
-127
-23% -$491K 0.03% 398
2015
Q1 		$2.25M Buy
563
+490
+671% +$2.24M 0.04% 350
2014
Q4 		$359K Sell
73
-6
-8% -$25.7K 0.01% 649
2014
Q3 		$322K Sell
79
-137
-63% -$514K 0.01% 667
2014
Q2 		$872K Buy
+216
New +$881K 0.01% 541

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's ACOR Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Acorda Therapeutics (ACOR) in Q3 2021, closing a stake of 6,760 shares — an estimated $645K sold.

Jacobs Levy Equity Management first reported a position in ACOR in Q2 2014 and held it in 28 quarters. The position peaked at $10.6M in Q2 2018. 32 funds tracked by Wall St. Rank hold ACOR as of Q3 2021.

  • Jacobs Levy Equity Management reported no remaining Acorda Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 6,760 Acorda Therapeutics shares in Q3 2021, an estimated $645K.
  • Jacobs Levy Equity Management first reported a position in Acorda Therapeutics in Q2 2014 and held it in 28 quarters.
  • Jacobs Levy Equity Management's Acorda Therapeutics position peaked at $10.6M in Q2 2018.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.